long intergenic non-protein coding RNA 1932Genealiases: []
Q-omics provides the consensus-scored LINC01932 profile across patient tissues and cancer cell-line models. LINC01932 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, LINC01932 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, LINC01932 RNA expression shows 11,361 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight COAD, HNSC, and ESCA as cancer lineages where LINC01932 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01932 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01932 survival associations across molecular data types. LINC01932 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01932 RNA expression–survival associations across cancer types. High LINC01932 expression shows unfavorable associations in KIRC, THYM and DLBC, but favorable associations in COAD, HNSC and LUSC. The COAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify COAD as the clearest survival context for LINC01932 RNA expression.
This table summarizes LINC01932 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01932. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01932 shows lower tumor expression in READ and PRAD and higher tumor expression in HNSC, UCEC and LUSC. The HNSC box plot shows higher LINC01932 RNA expression in tumor versus normal tissue (log2 FC = +1.834, t-test p < 0.001).
This table shows molecular features associated with LINC01932 in patient tissues and cancer cell lines. In patient samples, LINC01932 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
